US FDA Plans Rare Disease Center Of Excellence, But Not "That" Kind Of COE

A COE modeled after the Oncology Center of Excellence, which stakeholders had proposed, is not in the works, but rather a more virtual structure.

Business person standing in the middle of a circular maze with red arrow
After the OND reorganization, the rare disease program will continue helping assessors as needed. • Source: Shutterstock

The reorganization of the US Food and Drug Administration's Office of New Drugs will set the stage for another center of excellence, although not under the construct used for oncology.

OND's rare disease staff will be placed into its own division as part of the organizational flattening now under way....

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Rare Diseases

More from Pink Sheet